Long-acting injectable (LAI) antipsychotics have historically been initiated following repeated episodes of nonadherence, multiple hospitalizations, or failure of oral regimens.1 Emerging clinical consensus and accumulating real-world evidence are prompting a reconsideration of this sequencing, with increasing support for earlier LAI initiation as a proactive strategy in schizophrenia management.1
The case for earlier initiation is reinforced by a growing appreciation of first-episode psychosis as a distinct and important clinical window. First-episode psychosis is a clinically significant and heterogeneous phenomenon, spanning a broad range of diagnoses, illness trajectories, and outcomes. The spectrum extends from individuals with unknown risk status or attenuated psychotic features to those experiencing multiple relapses or unremitting illness.2 Biological, psychological, and social factors each contribute variably to risk and resilience, and research efforts are advancing polygenic risk scoring and biomarker panels to better identify individuals at elevated risk earlier in the disease course.2 Recognizing this early period as an opportunity, rather than simply a starting point, can meaningfully shape how clinicians approach treatment sequencing.
Nonadherence to oral antipsychotics is common, with a substantial proportion of patients discontinuing or inconsistently taking medications.3 Each relapse carries risks beyond symptom recurrence, including progressive neurobiological changes, functional decline, and increased difficulty achieving subsequent remission. Preventable relapses during the early illness phase can have lasting consequences on long-term trajectory and recovery potential, reinforcing the clinical rationale for addressing adherence structurally from the outset.2
LAI formulations address adherence variability structurally rather than relying on daily patient engagement. Consistent plasma levels reduce the clinical uncertainty associated with missed doses, and the injectable encounter provides a regular touchpoint for clinical monitoring.1 Introducing LAI therapy early in the treatment relationship allows clinicians to position these options as a deliberate, forward-looking choice rather than a response to prior setbacks. When the conversation happens before a crisis, patients can engage more thoughtfully, weigh preferences, and participate in a decision that reflects their goals for independence and long-term stability.
Patients with a history of nonadherence, limited social support, cognitive symptoms that complicate medication management, or preference for reduced daily treatment burden represent particularly strong candidates. However, expert guidance increasingly supports broader early consideration rather than restricting LAIs to high-risk subgroups alone.1
Normalizing LAI therapy as a possible first-line eligible approach, initiating discussion at or near diagnosis, and involving caregivers in that conversation can shift clinical culture in a direction that better aligns pharmacologic strategy with long-term recovery goals.
Take our schizophrenia quiz to see how your knowledge compares to your peers.
